Peripheral γδ T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma

References

• Godley PA, Taylor M. Renal cell carcinoma. Curr. Opin. Oncol. 13(3), 199–203 (2001).
   PubMed Web of Science ®Google Scholar
• Dhote R, Pellicer-Coeuret M, Thiounn N, Debre B, Vidal-Trecan G. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. Br. J. Urol. Int. 86(1), 20–27 (2000).
   Google Scholar
• Marshall FF, Lymphadenectomy for renal cell carcinoma. Br. J. Urol. Int. 95(Suppl. 2), 34 (2005).
   Google Scholar
• Storkel S, Eble JN, Adlakha K et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80(5), 987–989 (1997).
   PubMed Web of Science ®Google Scholar
• Pavlovich CP, Schmidt LS, Phillips JL. The genetic basis of renal cell carcinoma. Urol. Clin. North Am. 30(3), 437–454 (2003).
   PubMedGoogle Scholar
• Schmidt L, Junker K, Nakaigawa N et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18(14), 2343–2350 (1999).
   PubMed Web of Science ®Google Scholar
• Linehan WM, Vasselli J, Srinivasan R et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin. Cancer Res. 10(18 Pt 2), S6282–S6289 (2004).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo. Systemic therapy for renal cell carcinoma. J. Urol. 163(2), 408–417 (2000).
   PubMed Web of Science ®Google Scholar
• Fairlamb DJ. Spontaneous regression of metastases of renal cancer: a report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 47(8), 2102–2106 (1981).
   PubMed Web of Science ®Google Scholar
• Balch CM, Riley LB, Bae YJ et al. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch. Surg. 125(2), 200–205 (1990).
   PubMed Web of Science ®Google Scholar
• Muss HB et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J. Clin. Oncol. 5(2), 286–291 (1987).
   PubMed Web of Science ®Google Scholar
• Elhilali MM et al. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon γ-1b for the treatment of metastatic renal cell carcinoma. Can. Urol. Oncol. Grou. Br. J. Urol. Int. 86(6), 613–618 (2000).
   Google Scholar
• Fyfe G et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13(3), 688–696 (1995).
   PubMed Web of Science ®Google Scholar
• Negrier S et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur. J. Cancer Clin. Oncol. 25(Suppl. 3), S21–S28 (1989).
   Google Scholar
• Escudier B et al. High-dose interleukin-2 two days a week for metastatic renal cell carcinoma: a FNCLCC multicenter study. J. Immunother. Emphasis Tumor Immunol. 16(4), 306–312 (1994).
   PubMedGoogle Scholar
• Negrier S et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N. Engl. J. Med. 338(18), 1272–1278 (1998).
   PubMed Web of Science ®Google Scholar
• McDermott DF et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23(1), 133–141 (2005).
   PubMed Web of Science ®Google Scholar
• Law TM et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76(5), 824–832 (1995).
   PubMed Web of Science ®Google Scholar
• Figlin RA et al. Multicenter, randomized, Phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J. Clin. Oncol. 17(8), 2521–2529 (1999).
   PubMed Web of Science ®Google Scholar
• Escudier B et al. Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. Eur. J. Cancer 30A(8), 1078–1083 (1994).
   PubMedGoogle Scholar
• Panelli MC et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J. Immunother. 23(4), 487–498 (2000).
   PubMed Web of Science ®Google Scholar
• Kugler A, Stuhler G, Walden P et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med. 6(3), 332–336 (2000).
   PubMed Web of Science ®Google Scholar
• Childs RW, Igarashi T. The identification of renal cell carcinoma as a target for allogeneic based cancer immunotherapy. Exp. Nephrol. 10(3), 227–234 (2002).
   PubMedGoogle Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nature Rev. Cancer 4(1), 71–78 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo N. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10(9), 909–915 (2004).
   PubMed Web of Science ®Google Scholar
• Gerber D, Boucontet L, Pereira P. Early expression of a functional TCRbeta chain inhibits TCRγ gene rearrangements without altering the frequency of TCRγδ lineage cells. J. Immunol. 173(4), 2516–2523 (2004).
   PubMedGoogle Scholar
• Silva-Santos B, Pennington DJ, Hayday AC. Lymphotoxin-mediated regulation of γδ cell differentiation by αβ T-cell progenitors. Science 307(5711), 925–928 (2005).
   PubMedGoogle Scholar
• Hein WR, Mackay CR. Prominence of γ δ T-cells in the ruminant immune system. Immunol. Today 12(1), 30–34 (1991).
   PubMedGoogle Scholar
• Hayday AC. [γ][δ] cells: a right time and a right place for a conserved third way of protection. Ann. Rev. Immunol. 18, 975–1026 (2000).
   PubMed Web of Science ®Google Scholar
• Parker CM, Groh V, Band H et al. Evidence for extrathymic changes in the T-cell receptor γ/δ repertoire. J. Exp. Med. 171(5), 1597–1612 (1990).
   PubMed Web of Science ®Google Scholar
• Ismaili J et al. Human γδ T-cells induce dendritic cell maturation. Clin. Immunol. 103(3Pt 1), 296–302 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrick DA et al. Differential production of interferon-γ and interleukin-4 in response to Th1- and Th2-stimulating pathogens by γ δ T-cells in vivo. Nature 373(6511), 255–257 (1995).
   PubMed Web of Science ®Google Scholar
• Wang L et al. Human V γ 2V δ 2 T-cells produce IFN-γ and TNF-α with an on/off/on cycling pattern in response to live bacterial products. J. Immunol. 167(11), 6195–6201 (2001).
   PubMedGoogle Scholar
• Sicard H et al. In vivo Immunomanipulation of V{γ}9V{δ}2 T-cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J. Immunol. 175(8), 5471–5480 (2005).
   PubMed Web of Science ®Google Scholar
• Glatzel A et al. Patterns of chemokine receptor expression on peripheral blood γδ T-lymphocytes: strong expression of CCR5 is a selective feature of Vδ2/Vγ9γδ T-cells. J. Immunol. 168(10), 4920–4929 (2002).
   PubMedGoogle Scholar
• Dagna L, Iellem A, Biswas P et al. Skewing of cytotoxic activity and chemokine production, but not of chemokine receptor expression, in human type-1/-2 γδ T-lymphocytes. Eur. J. Immunol. 32(10), 2934–2943 (2002).
   Google Scholar
• Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human γδ T-cells. Science 309(5732), 264–268 (2005).
   PubMed Web of Science ®Google Scholar
• Davodeau F, Peyrat MA, Hallet MM et al. Close correlation between Daudi and mycobacterial antigen recognition by human γ δ T-cells and expression of V9JPC1 γ/V2DJC δ-encoded T-cell receptors. J. Immunol. 151(3), 1214–1223 (1993).
   PubMedGoogle Scholar
• Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T-cells. Science 279(5357), 1737–1740 (1998).
   PubMed Web of Science ®Google Scholar
• Spada FM, Grant EP, Peters PJ et al. Self-recognition of CD1 by γ/δ T-cells: implications for innate immunity. J. Exp. Med. 191(6), 937–948 (2000).
   PubMed Web of Science ®Google Scholar
• Dechanet J, Merville P, Lim A et al. Implication of γδ T-cells in the human immune response to cytomegalovirus. J. Clin. Invest. 103(10), 1437–1449 (1999).
   PubMedGoogle Scholar
• Constant P, Davodeau F, Peyrat MA et al. Stimulation of human γδ T-cells by nonpeptidic mycobacterial ligands. Science 264(5156), 267–270 (1994).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR. Natural and synthetic nonpeptide antigens recognized by human γδ T-cells. Nature 375(6527), 155–158 (1995).
   PubMed Web of Science ®Google Scholar
• Behr C, Poupot R, Peyrat MA et al. Plasmodium falciparum stimuli for human γδ T-cells are related to phosphorylated antigens of mycobacteria. Infect. Immun. 64(8), 2892–2896 (1996).
   PubMed Web of Science ®Google Scholar
• Belmant C, Espinosa E, Halary F et al. A chemical basis for selective recognition of nonpeptide antigens by human δ T-cells. Faseb J. 14(12), 1669–1670 (2000).
   PubMed Web of Science ®Google Scholar
• Bukowski JF, Morita CT, Brenner MB. Human γδ T-cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity 11(1), 57–65 (1999).
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Wilhelm M. Gamma/δ T-cell stimulation by pamidronate. N. Engl. J. Med. 340(9), 737–738 (1999).
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Feurle J et al. Stimulation of γδ T-cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2), 384–392 (2000).
   PubMed Web of Science ®Google Scholar
• Jomaa H, Feurle J, Luhs K et al. Vγ9/Vδ2 T-cell activation induced by bacterial low molecular mass compounds depends on the 1-deoxy-D-xylulose 5-phosphate pathway of isoprenoid biosynthesis. FEMS Immunol. Med. Microbiol. 25(4), 371–378 (1999).
   PubMedGoogle Scholar
• Rohmer M, Knani M, Simonin P, Sutter B, Sahm H. Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps leading to isopentenyl diphosphate. Biochem. J. 295(Pt 2), 517–524 (1993).
   PubMed Web of Science ®Google Scholar
• Feurle J, Espinosa E, Eckstein S et al. Escherichia coli produces phosphoantigens activating human γδ T-cells. J. Biol. Chem. 277(1), 148–154 (2002).
   PubMedGoogle Scholar
• Hintz M, Reichenberg A, Altincicek B et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human γδ T-cells in Escherichia coli. FEBS Lett. 509(2), 317–322 (2001).
   PubMed Web of Science ®Google Scholar
• Kato Y, Y. Tanaka, Miyagawa F, Yamashita S, Minato N. Targeting of tumor cells for human γδ T-cells by nonpeptide antigens. J. Immunol. 167(9), 5092–5098 (2001).
   PubMed Web of Science ®Google Scholar
• Gober HJ, Kistowska M, Angman L et al. Human T-cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197(2), 163–168 (2003).
   PubMed Web of Science ®Google Scholar
• Thompson K, Rojas-Navea J, Rogers MJ. Alkylamines cause V{gamma}9V{delta}2 T-cell activation and proliferation by inhibiting the mevalonate pathway. Blood (2005) (In Press).
   Google Scholar
• Espinosa E, Belmant C, Pont F et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human γ δ T-cells. J. Biol. Chem. 276(21), 18337–18344 (2001).
   PubMed Web of Science ®Google Scholar
• Bukowski JF, Morita CT, Tanaka Y et al. Vγ2Vδ2 TCR-dependent recognition of nonpeptide antigens and Daudi cells analyzed by TCR gene transfer. J. Immunol. 154(3), 998–1006 (1995).
   PubMed Web of Science ®Google Scholar
• Allison TJ, Winter CC, Fournie JJ, Bonneville M, Garboczi DN. Structure of a human γδ T-cell antigen receptor. Nature 411(6839), 820–824 (2001).
   PubMedGoogle Scholar
• Scotet E, Martinez LO, Grant E et al. Tumor recognition following Vγ9Vδ2 T-cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22(1), 71–80 (2005).
   PubMed Web of Science ®Google Scholar
• Bonneville M, Fournie JJ. Sensing cell stress and transformation through Vγ9Vδ2 T-cell-mediated recognition of the isoprenoid pathway metabolites. Microbes Infect. 7(3), 503–509 (2005).
   PubMedGoogle Scholar
• Fisch P, Malkovsky M, Kovats S et al. Recognition by human Vγ9/Vδ2 T-cells of a GroEL homolog on Daudi Burkitt’s lymphoma cells. Science 250(4985), 1269–1273 (1990).
   PubMed Web of Science ®Google Scholar
• Bank I, Book M, Huszar M et al. Vδ2+γδ T-lymphocytes are cytotoxic to the MCF 7 breast carcinoma cell line and can be detected among the T-cells that infiltrate breast tumors. Clin. Immunol. Immunopathol. 67(1), 17–24 (1993).
   PubMedGoogle Scholar
• Schilbach KE, Geiselhart A, Wessels JT, Niethammer D, Handgretinger R. Human γδ T-lymphocytes exert natural and IL-2-induced cytotoxicity to neuroblastoma cells. J. Immunother. 23(5), 536–548 (2000).
   PubMed Web of Science ®Google Scholar
• Wang MH, Chen YQ, Gercken J et al. Specific activation of human peripheral blood γ/δ + lymphocytes by sonicated antigens of Mycobacterium tuberculosis: role in vitro in killing human bladder carcinoma cell lines. Scand. J. Immunol. 38(3), 239–246 (1993).
   Google Scholar
• Ferrarini M, Heltai S, Pupa SM, Mernard S, Zocchi R. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing γδ(+) t-cell receptors. J. Natl Cancer Inst. 88(7), 436–441 (1996).
   PubMed Web of Science ®Google Scholar
• Fujimiya Y, Suzuki Y, Katakura R et al. In vitro interleukin-12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) γδ T-cells from glioblastoma patients. Clin. Cancer Res. 3(4), 633–643 (1997).
   PubMedGoogle Scholar
• Yamaguchi T, Fujimiya Y, Suzuki Y, Katakura R, Ebina T. A simple method for the propagation and purification of γδ T-cells from the peripheral blood of glioblastoma patients using solid-phase antiCD3 antibody and soluble IL-2. J. Immunol. Methods 205(1), 19–28 (1997).
   PubMedGoogle Scholar
• Liu Z, Guo BL, Gehrs BC, Nan L, Lopez RD. Ex vivo expanded human Vγ9Vδ2+ γδ-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J. Urol. 173(5), 1552–1556 (2005).
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Tanaka Y, Yagi J, Toma H, Uchiyama T. Gamma/δ T-cells provide innate immunity against renal cell carcinoma. Cancer Immunol. Immunother. 50(3), 115–124 (2001).
   PubMed Web of Science ®Google Scholar
• Viey E, Fromont G, Escudier B et al. Phosphostim-activated γδ T-cells kill autologous metastatic renal cell carcinoma. J. Immunol. 174(3), 1338–1347 (2005).
   PubMedGoogle Scholar
• Corvaisier M, Moreau-Aubry A, Diez E et al. V{γ}9V{δ}2 T-cell response to colon carcinoma cells. J. Immunol. 175(8), 5481–5488 (2005).
   PubMed Web of Science ®Google Scholar
• Malkovska V, Cigel FK, Armstrong N, Storer BE, Hong R. Antilymphoma activity of human γ δ T-cells in mice with severe combined immune deficiency. Cancer Res. 52(20), 5610–5616 (1992).
   PubMed Web of Science ®Google Scholar
• Zheng BJ, Chan KW, Im S et al. Antitumor effects of human peripheral γδ T-cells in a mouse tumor model. Int. J. Cancer 92(3), 421–425 (2001).
   PubMed Web of Science ®Google Scholar
• Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of human Vγ9Vδ2γδ T-cells in vitro and in SCID mice in vivo. J. Immunol. 173(11), 6767–6776 (2004).
   PubMed Web of Science ®Google Scholar
• Wilhelm M, Kunzmann V, Eckstein S et al. γδ T-cells for immune therapy of patients with lymphoid malignancies. Blood 102(1), 200–206 (2003).
   PubMed Web of Science ®Google Scholar
• Dieli F, Gebbia N, Poccia F et al. Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102(6), 2310–2311 (2003).
   PubMed Web of Science ®Google Scholar
• Laplace C, Soraya S, Tenaud I et al. Process to manufacture specific Vγ9Vδ2 T-lymphocytes cell therapeutic product from peripheral blood mononuclear cells (PBMC) using bromohydrin pyrophosphate (BRHPP) and interleukin 2 (IL-2). Proc. Am. Assoc. Cancer Res. 45, 5445 (2004) (Abstract).
   Google Scholar
• Bennouna J, Laplace C, Chidiac J et al. Determination of in vitro sensitivity of Vγ9Vδ2 T lymphocytes to a synthetic antigen (bromohydrin pyrophosphate, BrHPP) in patients with metastatic renal cell carcinoma (MRCC) and correlation with a large scale ex vivo expansion. Proc. Am. Assoc. Cancer Res. 45, 4710 (2004) (Abstract).
   Google Scholar
• Bennouna J, Mediom J, Rolland F et al. Phase I clinical trial of BromoHydrin PyroPhosphate, BrHPP (Phosphostim), a Vγ9Vδ2 T lymphocytes agonist in combination with low dose interleukin-2 in patients with solild tumors. Am. Soc. Clin. Oncol. (2005) (Abstract 2536).
   Google Scholar
• Gattinoni L, Klebanoff CA, Palmer DC et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T-cells. J. Clin. Invest. 115(6), 1616–1626 (2005).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850–854 (2002).
   PubMed Web of Science ®Google Scholar
• Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol. Immunother. 54(9), 915–925 (2005).
   PubMed Web of Science ®Google Scholar
• Coleman S, Clayton A, Mason MD et al. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Res. 65(15), 7000–7006 (2005).
   PubMed Web of Science ®Google Scholar
• Mancuso A, Sternberg CN. New treatments for metastatic kidney cancer. Can. J. Urol. 12(Suppl. 1), 66–70 (Discussion 105) (2005).
   PubMedGoogle Scholar
• Escudier B, Szczylik C, Eisen T et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Am. Soc. Clin. Oncol. 23, 4510 (2005) (Abstract).
   Google Scholar